Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older, of any gender.
• People whose cancer has not significantly affected their ability to carry out daily activities (a doctor would assess this using a standard scale called ECOG, with a score of 0 or 1).
• People who have been confirmed through a tissue or cell sample to have advanced or metastatic non-small cell lung cancer (NSCLC) that has spread or cannot be removed.
• People whose lung cancer has been confirmed as Stage III or IV (either squamous or non-squamous type, based on standard staging guidelines).
• People who have already received at least 2 but no more than 6 cycles of a standard first-line chemotherapy combination (platinum-based chemotherapy plus an immune checkpoint inhibitor), regardless of a particular protein marker (PD-L1) level.
• People whose cancer was first confirmed to have grown or spread (by a scan) while they were still receiving their first-line or maintenance immune checkpoint inhibitor treatment.
• People who have at least one measurable tumour (outside the brain) that can be detected on a CT or MRI scan, meeting specific size criteria.
• People whose kidneys, liver, bone marrow, blood clotting, and immune system are all functioning at an adequate level, as confirmed by blood tests.
• Women who could potentially become pregnant must have a negative blood pregnancy test before starting the study treatment.
• People who are willing and able to attend all scheduled visits, follow the treatment plan, and complete required scans and blood tests.

Who may not be able to join:

• People with an active urinary tract infection, pneumonia, or other ongoing systemic infection that has not been treated.
• People who currently have symptoms caused by cancer that has spread to the brain or central nervous system.
• People with any uncontrolled medical condition or illness that, in the doctor's opinion, could interfere with how the study treatment is assessed or affect patient safety.
• People who still have significant side effects (rated Grade 3 or higher on a standard medical scale) from previous cancer treatment — noting that hair loss and a skin condition called vitiligo are exceptions to this rule.
• People who needed immune-suppressing medications (other than low-dose steroids) to manage a side effect from prior treatment, or who are currently taking more than 10 mg per day of prednisone (or an equivalent steroid dose).
• People who are currently taking certain antiviral medications known to be active against vaccinia virus (such as cidofovir, vaccinia immunoglobulin, imatinib, or tecovirimat).
• People who have had major surgery within the 4 weeks before the planned start of treatment, or who have not sufficiently recovered from a previous surgery.
• People who have previously received a virus-based gene therapy or any treatment using a virus designed to destroy cells.
• People who have received a smallpox or monkeypox vaccination within the past year.
• People who have received any non-cancer vaccine (such as a flu shot or COVID-19 vaccine) within the 2 weeks before the planned first dose of study treatment.
• People with a significant skin condition, such as severe eczema, psoriasis, or an unhealed skin wound or ulcer, as assessed by the doctor.
• People with a known allergy or sensitivity to carboplatin, cisplatin, paclitaxel, nab-paclitaxel, docetaxel, or gentamicin (an ingredient in the study drug Olvi-Vec).
• People who have previously had a severe allergic reaction (Grade 3 or higher) to an immune checkpoint inhibitor or its ingredients.
• People with dementia, significantly altered mental state, or psychiatric or personal circumstances that could prevent them from giving informed consent or following the study requirements.

Important: Always verify eligibility with the trial site directly before applying.